Known as a leading Silicon Valley-based functional genomics startup, MEDiC Life Sciences has been supported by Ice Miller since 2022. The firm counseled MEDiC in securing a strategic investment by LG and Hanmi Pharmaceutical, two large Korean companies that will accelerate the adoption of MEDiC's cancer biomarker discovery solution by pharmaceutical partners. The firm has also guided MEDiC in a prior seed funding initiative garnering $8 million from a group of investors as well as its licensing and collaboration deals.

MEDiC emerged from discoveries made through Stanford University's SPARK program and has developed a next-generation functional genomics platform to identify novel cancer biomarkers and therapeutic targets for both its internal and external oncology pipelines. MEDiC has partnered with multiple pharmaceutical companies, including Bristol Myers Squibb, to advance its oncology pipelines, while also internally developing its own first-in-class cancer therapies.

Ice Miller works with life science startups, such as MEDiC, at various stages of growth by providing legal and strategic guidance from pre-funding through multiple rounds of venture financing, licensing, and collaboration deals.

This deal is representative of the cross-border transactions that Ice Miller’s Asia-Pacific practice has facilitated to aid our clients across the globe in ensuring that they achieve their objectives. Ice Miller partners TaeSoo Sean Kim and Josh Borean supported the client, with assistance from associate Simone Park.